# Phase 2 cancer trials recruiting: 2,432 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,432 trials in phase 2 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 cancer trials: 2,432 rows for $104.32, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 58 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,432
- Recruiting or not yet: 2,432
- Read on: November 19, 2026

## Trials

The 25 newest of 2,432, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 17, 2026 | NCT07943533 | HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | HER2-Positive, Limited Metastatic, Gastric Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943533) |
| November 17, 2026 | NCT07941843 | Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer | Damanhour University | Phase 2 | Not yet recruiting | Colorectal Cancer, Chemotherapy-Induced Peripheral Neuropathy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941843) |
| November 17, 2026 | NCT07941310 | A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer | Korea University Anam Hospital | Phase 2 | Not yet recruiting | Metastatic Colorectal Cancer, EGFR Amplified Colorectal Cancer | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941310) |
| November 16, 2026 | NCT07940062 | Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management | British Columbia Cancer Agency | Phase 2 | Not yet recruiting | Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma, Endometrial Carcinoma (EC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940062) |
| November 16, 2026 | NCT07938645 | PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 | Not yet recruiting | Biliary Tract Cancer (BTC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938645) |
| November 16, 2026 | NCT07938021 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC) | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938021) |
| November 16, 2026 | NCT07937696 | A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Colorectal Carcinoma, EPCAM Lynch Syndrome, Lynch Syndrome, MLH1 Lynch Syndrome, MSH2 Lynch Syndrome, MSH6 Lynch... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937696) |
| November 16, 2026 | NCT07937605 | KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937605) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| November 13, 2026 | NCT07935317 | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Breast Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935317) |
| November 13, 2026 | NCT07935226 | Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC | Harbin Medical University | Phase 2 | Not yet recruiting | Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935226) |
| November 13, 2026 | NCT07934745 | Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma | Fudan University | Phase 2 | Not yet recruiting | Anal Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934745) |
| November 12, 2026 | NCT07934121 | MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Platinum-Sensitive Recurrent Ovarian Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934121) |
| November 12, 2026 | NCT07933471 | Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Beijing Tsinghua Chang Gung Hospital | Phase 2 | Recruiting | Gastric Cancer (GC), Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933471) |
| November 12, 2026 | NCT07932067 | Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Head and Neck Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932067) |
| November 12, 2026 | NCT07931664 | Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | The Center for Clinical and Cosmetic Research | Phase 2 | Recruiting | Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ, Cutaneous Squamous Cell... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931664) |
| November 12, 2026 | NCT07931313 | PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer | Shanghai Gynecologic Oncology Group | Phase 2 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931313) |
| November 10, 2026 | NCT07928193 | Sac-TMT in Salivary Gland Cancers | Latin American Cooperative Oncology Group | Phase 2 | Not yet recruiting | Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928193) |
| November 10, 2026 | NCT07927998 | A Study of Retifanlimab After Chemoradiation in People With Anal Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927998) |
| November 9, 2026 | NCT07926698 | Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm... | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation, Acute Graft-Versus-Host Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926698) |
| November 9, 2026 | NCT07926477 | Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Colorectal Cancer | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926477) |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 9, 2026 | NCT07925268 | Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925268) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 117 |
| Sun Yat-sen University | 69 |
| Memorial Sloan Kettering Cancer Center | 47 |
| M.D. Anderson Cancer Center | 46 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 45 |
| Tianjin Medical University Cancer Institute and Hospital | 45 |
| National Cancer Institute (NCI) | 36 |
| The First Affiliated Hospital with Nanjing Medical University | 29 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 28 |
| Mayo Clinic | 21 |
| Dana-Farber Cancer Institute | 21 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 20 |
| Shanghai Zhongshan Hospital | 19 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 18 |
| City of Hope Medical Center | 17 |
| Fujian Cancer Hospital | 17 |
| Washington University School of Medicine | 17 |
| Henan Cancer Hospital | 17 |
| UNICANCER | 16 |
| Emory University | 16 |
| UNC Lineberger Comprehensive Cancer Center | 16 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 |
| Ruijin Hospital | 15 |
| University of Chicago | 14 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 14 |

## By country

| Country | Trials |
| --- | --- |
| China | 860 |
| United States | 821 |
| France | 112 |
| Canada | 101 |
| Spain | 94 |
| Italy | 82 |
| Germany | 66 |
| South Korea | 64 |
| Australia | 53 |
| United Kingdom | 51 |
| Japan | 47 |
| Taiwan | 45 |
| Netherlands | 43 |
| Belgium | 36 |
| Denmark | 31 |
| Brazil | 28 |
| Switzerland | 26 |
| Poland | 25 |
| Israel | 23 |
| Turkey (Türkiye) | 19 |
| Singapore | 15 |
| Austria | 14 |
| Norway | 14 |
| Russia | 13 |
| Hong Kong | 13 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Restaurant equipment suppliers in the United States](https://specstream.ai/data/businesses/restaurant-equipment-suppliers/united-states)
- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [Ear, nose and throat clinics in the United States](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/united-states)
- [Housing or property companies in the United States](https://specstream.ai/data/businesses/housing-or-property-companies/united-states)
- [Office cleaning companies in the United States](https://specstream.ai/data/businesses/office-cleaning-companies/united-states)
